Novo Nordisk's cagrilintide shows promise in Phase 3 trial Alan Nafiev posted on the topic LinkedIn Efficacy and safety of cagrilintide 2.4 mg in adults with overweight obesity: Data from REDEFINE 1 Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination In the REDEFINE 1 phase 3a trial, semaglutide at a dose of 2.4 mg with cagrilintide at a dose of 2.4 mg led to significant body weight reduction in adults without diabetes and